Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 30 Carcinoma, Hepatocellular 22 Small Cell Lung Carcinoma 15 Colorectal Neoplasms 14 Carcinoma, Non-Small-Cell Lung 14 Sarcoma 13 Ovarian Neoplasms 12 Breast Neoplasms 12 Triple Negative Breast Neoplasms 9 Nasopharyngeal Carcinoma 9 Esophageal Squamous Cell Carcinoma 9 Cholangiocarcinoma 9 Biliary Tract Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 6 Osteosarcoma 6 Lung Neoplasms 6 Pancreatic Neoplasms 5 Head and Neck Neoplasms 5 Esophageal Neoplasms 5 Uterine Cervical Neoplasms 4 Thyroid Neoplasms 4 Neoplasms 4 Melanoma 4 Solid Tumor 3 Recurrence 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Glioma 3 Carcinoma, Adenoid Cystic 3 Advanced Gastric Cancer 3

Interventions

Etoposide 2 olaparib 1 ceralasertib 1 apatinib 1 anlotinib 1 Platinum 1 Paclitaxel 1 Immune Checkpoint Inhibitors 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × SCLC × apatinib × Clear all

NCT06475209 2024-06-26

Adebrelimab + Apatinib in SCLC Maintenance Therapy

Tang-Du Hospital

Phase 2 Recruiting

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡